Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggestnews2026-03-19T10:45:27+00:00March 19th, 2026|Endpoints News|
Lawmakers signal willingness to counter China’s biotech gainsnews2026-03-18T19:41:47+00:00March 18th, 2026|Endpoints News|
Sanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing casenews2026-03-18T19:34:40+00:00March 18th, 2026|Endpoints News|
FDA opens door to RMAT designations for therapies on clinical holdnews2026-03-18T18:54:41+00:00March 18th, 2026|Endpoints News|
FDA approves J&J’s psoriasis pill Icotyde with $5B+ peak sales potentialnews2026-03-18T13:39:56+00:00March 18th, 2026|Endpoints News|
Aspen’s personalized Parkinson’s therapy shows early promisenews2026-03-18T13:00:44+00:00March 18th, 2026|Endpoints News|
CMS innovation center to expand team focused on drug pricesnews2026-03-17T19:07:25+00:00March 17th, 2026|Endpoints News|
Aldeyra dry eye drug gets third rejection from FDA, triggering stock slidenews2026-03-17T18:30:14+00:00March 17th, 2026|Endpoints News|
Drugmakers consider licensing deal tweaks to soften MFN impactnews2026-03-17T16:47:55+00:00March 17th, 2026|Endpoints News|
Rhythm’s Imcivree fails Phase 3 rare form obesity trialnews2026-03-17T13:48:31+00:00March 17th, 2026|Endpoints News|
